InforMax Reports Improved Q2 Losses; Beats Analysts Projections | GenomeWeb

NEW YORK, Aug. 1 - InforMax on Wednesday reported a slight improvement in second-quarter losses on top of a nearly 130 percent surge in revenues over the same period last year.

The Bethesda, Md.-based bioinformatics company reported a $0.17 diluted net loss per share, beating by 42 cents its earnings per share over the same period last year and by 1 penny a consensus of analysts polled by Thomson Financial/First Call.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."